The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of factor VIII-containing products to evaluate the risk of neutralizing antifactor VIII alloantibodies (inhibitors) developing in patients initiating treatment for hemophilia A, the agency announced today.

The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A.

The U.S. Food and Drug Administration today approved Coagadex, Coagulation Factor X (Human), for hereditary Factor X (10) deficiency.

The US Food and Drug Administration (FDA) has approved Bayer AG's unmodified, full-length recombinant antihemophilic factor VIII product, Kovaltry, for the treatment of hemophilia A in children and adults, the company said.

About half of the U.S. population has at least one of three major risk factors for heart disease: high blood pressure, high cholesterol, or diabetes.

NIH-funded study finds that the age of a donor is not a factor in most corneal transplants.

Is it all about the chromosomes? Find out why women may be healthier and live longer than men.

A major risk for heart disease and stroke, race, place, and gender appear to be strongly associated with high blood pressure.

The US Food and Drug Administration (FDA) today approved a drug for children and adults with hemophilia B called albutrepenonacog alfa (Idelvion, CSL Behring), which combines albumin with factor IX to reduce injection frequency.

The U.S. Food and Drug Administration yesterday approved Rixubis [Coagulation Factor IX (Recombinant)] for use in people with hemophilia B who are 16 years of age and older.

The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant).

The U.S. Food and Drug Administration approved Tretten, the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, known as congenital Factor XIII A-subunit deficiency.

Screening and diagnostic testing can affect the incidence of certain cancers and result in "self-fulfilling" risk factors associated with those cancers, according to a new essay by two major figures in the US cancer scene.

The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A.

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD).

The world's top 10 most expensive drugs are all orphan drugs for rare and ultrarare diseases, according to a new analysis.

The US Food and Drug Administration (FDA) has approved antihemophilic factor (recombinant), single chain (rVIII-single chain; Afstyla, CSL Behring) for on-demand treatment and control of bleeding episodes, routine prophylaxis to decrease the frequency of bleeding episodes, and perioperative management of bleeding in children and adults with hemophilia A (congenital factor VIII deficiency).

Illegal synthetic cannabis products laced with rat poison continue to be sold in the United States and pose a significant health risk not only to people who use these products but also the US blood supply, the US Food and Drug Administration (FDA) said this week in an update on the ongoing problem.

The U.S. Food and Drug Administration today approved Entyvio (vedolizumab) injection to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn's disease.

The chronic skin disorder psoriasis may raise the risk of diabetes, a large study shows.

Nonsteroidal anti-inflammatory drug (NSAID) use during acute respiratory infection (ARI) increases the risk for acute myocardial infarction (AMI) 3.4-fold if taken by mouth and 7.2-fold with parenteral dosing compared with baseline risk without NSAID use or ARI, according to a report published online February 2 in the Journal of Infectious Diseases.

A person's risk of heart disease is currently estimated in the short-term, meaning the likelihood of having heart disease in the next 10 years. This may be incorrect.

Need another reason to take life in stride and heed the advice, "Don't sweat the small stuff"?